Abeona Therapeutics (FRA:PCJ) ROE % Adjusted to Book Value : -14.95% (As of Dec. 2024)

View and export this data going back to 1980. Start your Free Trial

What is Abeona Therapeutics ROE % Adjusted to Book Value?

Abeona Therapeutics's ROE % for the quarter that ended in Dec. 2024 was -85.24%. Abeona Therapeutics's PB Ratio for the quarter that ended in Dec. 2024 was 5.70. Abeona Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -14.95%.

Abeona Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Abeona Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abeona Therapeutics ROE % Adjusted to Book Value Chart

Abeona Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-166.32

-104.61

-65.98

-28.96

-38.38

Abeona Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-40.25	-	39.29	-36.83	-14.95

Competitive Comparison of Abeona Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Abeona Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abeona Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abeona Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Abeona Therapeutics's ROE % Adjusted to Book Value falls into.

Save Embed

;

Save Embed

;

Abeona Therapeutics ROE % Adjusted to Book Value Calculation

Abeona Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-218.77%	/	5.70
	=	-38.38%

Abeona Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-85.24%	/	5.70
	=	-14.95%

Abeona Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Abeona Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Abeona Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abeona Therapeutics Inc (FRA:PCJ) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

ABEO:USA 0H7R:UK PCJ:Germany

Address

6555 Carnegie Avenue, 4th Floor, Cleveland, OH, USA, 44103

Website

https://www.abeonatherapeutics.com

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.

Abeona Therapeutics Headlines

No Headlines